Hims & Hers Health, Inc. $HIMS Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 29.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 92,317 shares of the company’s stock after buying an additional 21,204 shares during the period. Intech Investment Management LLC’s holdings in Hims & Hers Health were worth $2,998,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Arista Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $325,000. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after buying an additional 608,950 shares during the period. New Age Alpha Advisors LLC boosted its holdings in shares of Hims & Hers Health by 45.8% in the 4th quarter. New Age Alpha Advisors LLC now owns 54,657 shares of the company’s stock valued at $1,775,000 after buying an additional 17,170 shares during the period. Axxcess Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $914,000. Finally, Leonteq Securities AG acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $228,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells bought 48,400 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the purchase, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 212,807 shares of company stock valued at $5,473,644 in the last ninety days. Company insiders own 11.76% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on HIMS. Citigroup upped their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. TD Cowen decreased their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research report on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $28.70.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers completed its acquisition of Eucalyptus, giving it an immediate presence in Australia, Canada, Germany, and Japan and broadening its international growth opportunities. Article Title
• Positive Sentiment: The acquisition strengthens Hims & Hers’ position in clinically backed weight-management care and expands access to its digital health platform in major international markets. Article Title
• Neutral Sentiment: The company is also framing the deal as a step toward becoming the “world’s largest consumer health platform,” which may help sentiment but does not by itself guarantee near-term profitability. Article Title
• Negative Sentiment: Despite the expansion story, the stock remains highly valued and volatile, and recent investor focus on an “undervalued” thesis suggests the market may still be debating whether growth is enough to justify the price. Article Title

Hims & Hers Health Trading Down 0.9%

Shares of NYSE:HIMS opened at $27.51 on Wednesday. The company has a 50 day moving average of $24.16 and a 200-day moving average of $27.29. The firm has a market cap of $6.37 billion, a P/E ratio of -305.68, a P/E/G ratio of 53.87 and a beta of 2.37. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.